vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and KeyCorp (KEY). Click either name above to swap in a different company.
KeyCorp is the larger business by last-quarter revenue ($1.9B vs $1.1B, roughly 1.7× Elanco Animal Health Inc). KeyCorp runs the higher net margin — 26.8% vs -24.1%, a 51.0% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 10.2%). Over the past eight quarters, KeyCorp's revenue compounded faster (12.9% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Key is a Japanese visual novel studio known for making dramatic and plot-oriented titles. It was formed on July 21, 1998, as a brand under the publisher Visual Arts, and is located in Kita, Osaka.
ELAN vs KEY — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.9B |
| Net Profit | $-276.0M | $522.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | — |
| Net Margin | -24.1% | 26.8% |
| Revenue YoY | 12.2% | 10.2% |
| Net Profit YoY | -3350.0% | 28.9% |
| EPS (diluted) | $-0.55 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.2B | $1.8B | ||
| Q4 24 | $1.0B | $865.0M | ||
| Q3 24 | $1.0B | $695.0M | ||
| Q2 24 | $1.2B | $1.5B |
| Q1 26 | — | $522.0M | ||
| Q4 25 | $-276.0M | $510.0M | ||
| Q3 25 | $-34.0M | $489.0M | ||
| Q2 25 | $11.0M | $425.0M | ||
| Q1 25 | $67.0M | $405.0M | ||
| Q4 24 | $-8.0M | $-244.0M | ||
| Q3 24 | $364.0M | $-410.0M | ||
| Q2 24 | $-50.0M | $274.0M |
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | -22.6% | 32.3% | ||
| Q3 25 | -4.4% | 31.8% | ||
| Q2 25 | 2.0% | 29.3% | ||
| Q1 25 | 5.0% | 29.0% | ||
| Q4 24 | -5.0% | -92.6% | ||
| Q3 24 | 54.3% | -72.8% | ||
| Q2 24 | -2.7% | 22.0% |
| Q1 26 | — | 26.8% | ||
| Q4 25 | -24.1% | 25.4% | ||
| Q3 25 | -3.0% | 25.8% | ||
| Q2 25 | 0.9% | 23.1% | ||
| Q1 25 | 5.6% | 22.8% | ||
| Q4 24 | -0.8% | -54.7% | ||
| Q3 24 | 35.3% | -59.0% | ||
| Q2 24 | -4.2% | 18.0% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-0.55 | $0.43 | ||
| Q3 25 | $-0.07 | $0.41 | ||
| Q2 25 | $0.02 | $0.35 | ||
| Q1 25 | $0.13 | $0.33 | ||
| Q4 24 | $-0.01 | $-0.30 | ||
| Q3 24 | $0.73 | $-0.47 | ||
| Q2 24 | $-0.10 | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $11.8B |
| Total DebtLower is stronger | $3.9B | $10.9B |
| Stockholders' EquityBook value | $6.5B | $20.0B |
| Total Assets | $13.4B | $188.7B |
| Debt / EquityLower = less leverage | 0.60× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $11.8B | ||
| Q4 25 | $545.0M | $10.2B | ||
| Q3 25 | $505.0M | $13.3B | ||
| Q2 25 | $539.0M | $11.6B | ||
| Q1 25 | $487.0M | $15.3B | ||
| Q4 24 | $468.0M | $17.5B | ||
| Q3 24 | $490.0M | $22.8B | ||
| Q2 24 | $416.0M | $15.5B |
| Q1 26 | — | $10.9B | ||
| Q4 25 | $3.9B | $9.9B | ||
| Q3 25 | $4.0B | $10.9B | ||
| Q2 25 | $4.1B | $12.1B | ||
| Q1 25 | $4.4B | $12.4B | ||
| Q4 24 | $4.3B | $12.1B | ||
| Q3 24 | $4.4B | $15.7B | ||
| Q2 24 | $5.7B | $16.9B |
| Q1 26 | — | $20.0B | ||
| Q4 25 | $6.5B | $20.4B | ||
| Q3 25 | $6.7B | $20.1B | ||
| Q2 25 | $6.8B | $19.5B | ||
| Q1 25 | $6.4B | $19.0B | ||
| Q4 24 | $6.1B | $18.2B | ||
| Q3 24 | $6.5B | $16.9B | ||
| Q2 24 | $5.9B | $14.8B |
| Q1 26 | — | $188.7B | ||
| Q4 25 | $13.4B | $184.4B | ||
| Q3 25 | $13.6B | $187.4B | ||
| Q2 25 | $13.7B | $185.5B | ||
| Q1 25 | $12.9B | $188.7B | ||
| Q4 24 | $12.6B | $187.2B | ||
| Q3 24 | $13.3B | $189.8B | ||
| Q2 24 | $13.8B | $187.4B |
| Q1 26 | — | 0.54× | ||
| Q4 25 | 0.60× | 0.49× | ||
| Q3 25 | 0.59× | 0.54× | ||
| Q2 25 | 0.61× | 0.62× | ||
| Q1 25 | 0.69× | 0.65× | ||
| Q4 24 | 0.70× | 0.67× | ||
| Q3 24 | 0.67× | 0.93× | ||
| Q2 24 | 0.96× | 1.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $2.2B | ||
| Q3 25 | $219.0M | $396.0M | ||
| Q2 25 | $237.0M | $1.2B | ||
| Q1 25 | $-4.0M | $-140.0M | ||
| Q4 24 | $177.0M | $664.0M | ||
| Q3 24 | $162.0M | $-1.2B | ||
| Q2 24 | $200.0M | $-217.0M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $2.1B | ||
| Q3 25 | $127.0M | $367.0M | ||
| Q2 25 | $180.0M | $1.2B | ||
| Q1 25 | $-69.0M | $-150.0M | ||
| Q4 24 | $130.0M | $599.0M | ||
| Q3 24 | $120.0M | $-1.2B | ||
| Q2 24 | $166.0M | $-230.0M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 104.8% | ||
| Q3 25 | 11.2% | 19.4% | ||
| Q2 25 | 14.5% | 65.8% | ||
| Q1 25 | -5.8% | -8.5% | ||
| Q4 24 | 12.7% | 69.2% | ||
| Q3 24 | 11.7% | -175.8% | ||
| Q2 24 | 14.0% | -15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 5.3% | ||
| Q3 25 | 8.1% | 1.5% | ||
| Q2 25 | 4.6% | 1.3% | ||
| Q1 25 | 5.4% | 0.6% | ||
| Q4 24 | 4.6% | 7.5% | ||
| Q3 24 | 4.1% | 2.4% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.33× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | 21.55× | 2.90× | ||
| Q1 25 | -0.06× | -0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | -0.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
KEY
| Net Interest Income | $1.2B | 63% |
| Noninterest Income | $723.0M | 37% |
